Aktiebolag v. Andrx Pharmaceuticals, Inc.

208 F.R.D. 92, 64 U.S.P.Q. 2d (BNA) 1331, 2002 U.S. Dist. LEXIS 9985
CourtDistrict Court, S.D. New York
DecidedJune 1, 2002
DocketNos. 99 Civ. 8926 (BSJ), 99 Civ. 9887 (BSJ); MDL Docket No. 1291
StatusPublished
Cited by30 cases

This text of 208 F.R.D. 92 (Aktiebolag v. Andrx Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aktiebolag v. Andrx Pharmaceuticals, Inc., 208 F.R.D. 92, 64 U.S.P.Q. 2d (BNA) 1331, 2002 U.S. Dist. LEXIS 9985 (S.D.N.Y. 2002).

Opinion

Opinion

JONES, District Judge.

I. INTRODUCTION Andrx challenged Astra’s assertions of attorney-client privilege and/or work product protection for seventy-five documents for Phase IV of this trial. (See Letter from Astra to court of 5/29/02; Letter from Andrx to court of 5/24/02.) Andrx challenged the following documents, which were listed on several different privilege logs: documents 59, 334, 367, 442, 442-1, 521, 526, 527, 530, 531, 531-1, 533, 533-1, 533-2, 535, 535-1, 543, 578, 578-1, 580, 580-1, 587, 588, 616, 616-1, and 623 on the May 15, 2002, Supplemental ’281 Privilege Log; documents 116-1, 197-1, 200-2, 211-2, 217, 223, 223-1, 235-1, 237-1, 245-1, 263-1-1, 430-1, 484-1, 585,1 827, and 836-1 on the April 24 Kim and Chang Log;2 documents 235, 246, 1524, 1525, 1544,1546, 1550, 2133, 2134, 2142, 2421, 2534, 2585, 2587, 2588,3 and 2605 on the Astra May 2 Categorical Log and May 7 Supplement; documents 712-1, 712-2, 731-1, and 775-2 on the April 30, 2002, Kim and Chang Supplemental Privilege Log; documents 984A, 990, 1627, 2289, 2292,4 2412, 2413, and 2414 on the May 2 Supplement to the 1999 Categorical Log; and documents 3059, 3059A, 3059B, 3059C, and 3059D on the May 10 Supplement to the 1999 Categorical Log.5 (See id.)

Because of the complexity of this case, this court decided that an in camera inspection of the documents would be necessary to decide properly the issues raised by Andrx’s challenges. Astra submitted the challenged documents to the court for review in a series of five in camera submissions. The court reviewed each of the documents individually. After conducting a complete in camera review of all of the challenged documents, the court ordered the immediate production of twenty-two of the challenged documents either in their entirety or with appropriate redactions. (See Order of 5/27/02.) The court also provided Andrx with a redacted copy of an additional document during a conference on May 30, 2002. The court addresses the issues raised by each of Andrx’s challenges in detail below.

Astra’s first in camera submission contained documents 116-1, 197-1, 200-2, 211-2, 217, 223, 223-2, 235-1, 237-1, 245-1, 263-1-1, 430-1, 484-1, 827, and 836-1. All of those documents were maintained in the files of the Korean law firm Kim and Chang and related to Korean proceedings, including those between Astra and CKD. (Ryberg Deck of 4/29/02, 112.) There are two general categories of documents at issue in the first in camera submission: (1) communications between employees of Astra in Sweden, including Astra’s in-house counsel, and Astra’s outside counsel in Korea regarding matters pending in the Korean courts and before the Korean Intellectual Property Office (“KIPO”) and (2) internal communications among Astra employees in Sweden that were transmitted to Astra’s outside counsel in Korea.

Astra’s second in camera submission contained documents 235, 246, 334, 367, 442, 442-1, 521, 526, 527, 543, 578, 578-1, 580, 580-1, 585, 587, 588, 616, 616-1, 623, 1524, 1525, 1544, 1546,1550, 2133, 2134, 2142, 2421, [96]*962534, 2585, 2587, 2588, and 2605. With the exception of document 585, which was maintained in the files of Kim and Chang, the documents were maintained either by Astra’s legal department, Astra’s patent department, or the offices of Astra’s in-house scientific advisors. Documents 235, 246, 585, 1524, 1525, 1544, 1546, 1550, 2133, 2134, 2142, 2421, 2534, 2585, 2587, 2588, and 2605 are either (1) communications between Astra employees in Sweden and in-house lawyers or Kim and Chang lawyers or (2) communications between Astra employees, including lawyers, Kim and Chang lawyers, and Professor C.T. Rhodes. All of those documents relate to Korean litigation between Astra and CKD. Documents 442, 442-1, 616, and 616-1 are either (1) communications between Astra employees in Sweden and in-house lawyers or (2) communications between Astra employees, including lawyers, and Astra’s German counsel Wolfgang Dost. These documents relate to Astra’s patents and pending applications. Documents 334, 521, 526, 527, 543, 578, 578-1, 580, 580-1, 587, 588, and 623 are communications between or among Astra employees and in-house counsel or (2) communications between Astra employees, including lawyers, and Astra’s U.S. counsel. These documents relate to one of Astra’s U.S. patent applications or its PCT and Swedish priority applications. Document 367 relates to a foreign patent application never submitted for review.

Astra’s third in camera submission contained documents 503, 531, 531-1, 533, 533-1, 533-2, 535, and 535-1. All of those documents were maintained originally in the files of Birgitta Larsson, an Astra employee responsible for prosecuting, or coordinating with Astra’s outside counsel in prosecuting, patent applications around the world. (Lars-son Decl. of 5/15/02, 11111-2.) Each of the documents is a communication between Lars-son and either American or Korean outside counsel for Astra.

Astra’s fourth in camera submission contained documents 59, 712-1, 712-2, 731-1, 775-2, 984A, 990, 2289, 2292, 2412, 2413, 2414, 3059, 3059A, 3059B, 3059C, and 3059D. Those documents were maintained by Astra’s legal department, Astra’s patent department, the offices of Astra’s in-house scientific advis-ors or in the files of the Korean law firm Kim and Chang. (Ryberg Decl. of 5/23/02, 112.)

Astra’s fifth in camera submission consisted solely of document 1627, (see Letter from Astra to court of 5/29/02), which was requested after this court issued its initial order on May 27, 2002, requiring Astra to produce some of the challenged documents.

II. RELEVANCE

As a threshold issue, the court considered the relevance of each of the challenged documents. The determination of whether material is relevant in a patent case is governed by Federal Circuit law when the material relates to an issue of substantive patent law. See Advanced Cardiovascular Sys., Inc. v. Medtronic, Inc., 265 F.3d 1294, 1307 (Fed.Cir.2001); Midwest Indus., Inc. v. Karavan, 175 F.3d 1356, 1359 (Fed.Cir.1999) (citing Truswal Sys. Corp. v. Hydro-Air Eng’g, Inc., 813 F.2d 1207, 1212 (Fed.Cir. 1987)). Applying Federal Circuit law, the court finds that it need not address Andrx’s challenges to documents 59, 367, 2412, 2413, 2414, 3059, 3059A, 3059B, 3059C, and 3059D because the documents are irrelevant to the issues raised by the claims and defenses asserted in Phase IV of this trial.

III. CHOICE OF LAW

A. REGIONAL OR FEDERAL CIRCUIT

In deciding issues in a patent case, a district court applies the law of the circuit in which it sits with respect to nonpatent issues and the law of the Federal Circuit to issues of substantive patent law. Institut Pasteur v. Cambridge Biotech Corp., 186 F.3d 1356, 1358 (Fed.Cir.1999). An issue “that is not itself a substantive patent law issue is nonetheless governed by Federal Circuit law if the issue pertains to patent law, if it bears an essential relationship to matters committed to [the exclusive control of the Federal Circuit] by statute, or if it clearly implicates the jurisprudential responsibilities of [the Federal Circuit] in a field within its exclusive jurisdiction.” Midwest Indus., Inc. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
208 F.R.D. 92, 64 U.S.P.Q. 2d (BNA) 1331, 2002 U.S. Dist. LEXIS 9985, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aktiebolag-v-andrx-pharmaceuticals-inc-nysd-2002.